Nu Skin Enterprises (NUS)
(Delayed Data from NYSE)
$7.22 USD
+0.67 (10.23%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $7.23 +0.01 (0.14%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.22 USD
+0.67 (10.23%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $7.23 +0.01 (0.14%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
Coty (COTY) in Focus: Stock Moves 5.4% Higher
by Zacks Equity Research
Coty (COTY) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Nu Skin Enterprises' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Nu Skin Enterprises
NUS vs. PORBF: Which Stock Is the Better Value Option?
by Zacks Equity Research
NUS vs. PORBF: Which Stock Is the Better Value Option?
Inter Parfums (IPAR) Q1 Earnings Top Estimates, Sales Drop Y/Y
by Zacks Equity Research
Inter Parfums' (IPAR) first-quarter 2020 results reflect coronavirus-led hurdles. The Middle East and Asia were most affected.
Cosmetics Industry Outlook Prospects Dimmed by Coronavirus Woes
by Vrishali Bagree
The Cosmetics space appears to be under pressure, thanks to coronavirus-led concerns like major travel restrictions, delay in product launches and temporary store closures in some regions.
Nu Skin's (NUS) Q1 Earnings Beat Estimates, Decline Y/Y
by Zacks Equity Research
Nu Skin's (NUS) first-quarter 2020 results reflect lower earnings and sales. Foreign currency headwinds and reduced sales leaders in Mainland China hurt results.
Nu Skin Enterprises (NUS) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 50.00% and 6.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's How Nu Skin (NUS) is Placed Ahead of Q1 Earnings
by Zacks Equity Research
Impacts from foreign currency headwinds are likely to get reflected on Nu Skin's (NUS) first-quarter 2020 results. Also, restrictions on travel amid coronavirus are a concern.
Analysts Estimate Nu Skin Enterprises (NUS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inter Parfums Q1 Sales Soft, Launches Delayed Amid Coronavirus
by Zacks Equity Research
Inter Parfums (IPAR) reports dismal sales numbers in first-quarter 2020. Also, the company postponed launches due to growing coronavirus concerns.
Inter Parfums (IPAR) Withdraws 2020 View Due to Coronavirus
by Zacks Equity Research
Due to the coronavirus outbreak and its impact on revenues and costs, Inter Parfums (IPAR) has withdrawn full-year 2020 guidance.
Ulta Beauty Enhances Financial Flexibility Amid Coronavirus
by Zacks Equity Research
Ulta Beauty (ULTA) announces that it has drawn down $800 million under its revolving credit facility in order to maintain financial flexibility amid the coronavirus outbreak.
Why Is Nu Skin (NUS) Down 37.4% Since Last Earnings Report?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Nu Skin Mainland China Woes Worsen Due to Coronavirus?
by Zacks Equity Research
Nu Skin (NUS) anticipates sales in Mainland China to decline 20-25% in 2020. The company puts meetings on hold in the region due to the coronavirus outbreak.
Coronavirus Steals Glitter Off These 3 Cosmetic Stocks
by Vrishali Bagree
Coronavirus-led worries weigh on the guidance of these cosmetic stocks due to reduced global travel and sluggish traffic.
Nu Skin's (NUS) Q4 Earnings Meet Estimates, Down Year on Year
by Zacks Equity Research
Nu Skin's (NUS) fourth-quarter 2019 results reflect lower earnings and sales. Further, management expects the coronavirus outbreak to hurt Mainland China sales in 2020.
Here's How Nu Skin (NUS) is Placed Ahead of Q4 Earnings
by Zacks Equity Research
Impacts from foreign currency headwinds are likely to get reflected in Nu Skin's (NUS) fourth-quarter 2019 results. However, the company is on track with product launches and programs to bolster sales leaders.
Earnings Preview: Nu Skin Enterprises (NUS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Nu Skin (NUS) Down 4.4% Since Last Earnings Report?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin Plunges in 6 Months, Mainland China Woes Persist
by Zacks Equity Research
Nu Skin (NUS) is battling headwinds in Mainland China thanks to increased scrutiny by the government. Also, management provides an unimpressive view for 2019.
Nu Skin's (NUS) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Nu Skin's (NUS) third-quarter earnings are affected by limited sales meetings in Mainland China.
Nu Skin Enterprises (NUS) Tops Q3 Earnings Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 3.95% and -2.57%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's How Nu Skin (NUS) Looks Just Ahead of Q3 Earnings
by Zacks Equity Research
Nu Skin's (NUS) third-quarter 2019 results are expected to reflect impacts of foreign currency headwinds.
Earnings Preview: Nu Skin Enterprises (NUS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Estee Lauder Maintain Momentum on Solid Travel Retail?
by Zacks Equity Research
Estee Lauder's (EL) strong online business and travel retail network are likely to drive growth. The company also benefits from a solid presence in emerging markets.